10-May-2024
Benzinga (Thu, 9-May 5:49 AM ET)
Vanda Pharmaceuticals GAAP EPS of -$0.07, revenue of $47.46M
Seeking Alpha News (Wed, 8-May 4:03 PM ET)
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
PRNewswire (Wed, 8-May 4:01 PM ET)
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
PRNewswire (Tue, 7-May 11:17 AM ET)
Business Wire (Tue, 7-May 9:00 AM ET)
Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
PRNewswire (Tue, 30-Apr 4:30 PM ET)
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
Globe Newswire (Thu, 25-Apr 8:05 AM ET)
PRNewswire (Mon, 22-Apr 7:13 PM ET)
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
PRNewswire (Wed, 17-Apr 10:21 AM ET)
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
PRNewswire (Wed, 17-Apr 9:02 AM ET)
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
Vanda Pharmaceuticals trades on the NASDAQ stock market under the symbol VNDA.
As of May 10, 2024, VNDA stock price climbed to $5.04 with 1,337,705 million shares trading.
VNDA has a beta of -0.27, meaning it tends to be less sensitive to market movements. VNDA has a correlation of 0.00 to the broad based SPY ETF.
VNDA has a market cap of $289.96 million. This is considered a Small Cap stock.
Last quarter Vanda Pharmaceuticals reported $47 million in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.12.
In the last 3 years, VNDA stock traded as high as $21.86 and as low as $3.30.
The top ETF exchange traded funds that VNDA belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.
VNDA stock has underperformed the market in the last year with a return of -25.7%, while SPY returned +27.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in VNDA shares. However, VNDA has outperformed the market in the last 3 month and 2 week periods, returning +21.2% and +9.1%, while SPY returned +4.2% and +2.5%, respectively. This indicates VNDA has been having a stronger performance recently.
VNDA support price is $4.82 and resistance is $5.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VNDA stock will trade within this expected range on the day.